Słowa kluczowe
niedokrwistość
hemoglobina
erytropoetyna
erytropoeza
Jak cytować
Abstrakt
Flozyny są lekami hipoglikemizującymi, które poza kontrolą glikemii wykazują także korzystny wpływ na układ sercowo-naczyniowy oraz nerki. Badania wskazują, że leki te wpływają na proces erytropoezy poprzez poprawę funkcji komórek nerkowych produkujących erytropoetynę, aktywację szlaku czynnika indukowanego niedotlenieniem 2α, obniżenie stężenia hepcydyny oraz zwiększenie dostępności żelaza wykorzystywanego do syntezy hemoglobiny. Liczne badania oraz metaanalizy potwierdzają, że stosowanie flozyn wiąże się ze zmniejszeniem ryzyka niedokrwistości oraz z istotnym wzrostem stężenia hemoglobiny i hematokrytu w różnych grupach pacjentów. Jednocześnie obserwuje się zwiększoną częstość nadkrwistości. W przeglądzie opisano mechanizmy wpływu flozyn na erytropoezę i przedstawiono badania przedkliniczne oraz kliniczne.
Bibliografia
1. Suprapti E., Hadju V., Ibrahim E. et al.: Anemia: Etiology, Pathophysiology, Impact, and Prevention: A Review. Iran J Public Health 2025; 54(3): 509-520.
2. Turner J., Parsi M., Badireddy M.: Anemia. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; https://www.ncbi.nlm. nih.gov/books/NBK499994/ (accessed 7.12.2025).
3. Weiss G., Ganz T., Goodnough L.T.: Anemia of inflammation. Blood 2019; 133(1): 40-50.
4. Santini V.: Anemia as the Main Manifestation of Myelodysplastic Syndromes. Semin Hematol 2015; 52(4): 348356.
5. Weiss G., Ganz T., Goodnough L.T.: Anemia of inflammation. Blood 2019; 133(1): 40-50.
6. Kim S., Koh H.: Nutritional aspect of pediatric inflammatory bowel disease: its clinical importance. Korean J Pediatr 2015; 58(10): 363-368.
7. Wouters H.J.C.M., van der Klauw M.M., de Witte T. et al.: Association of anemia with health-related quality of life and survival: a large population-based cohort study. Haematologica 2019; 104(3): 468-476.
8. Wiciński M., Liczner G., Cadelski K. et al.: Anemia of Chronic Diseases: Wider Diagnostics-Better Treatment? Nutrients 2020; 12(6): 1784.
9. Patel K.V., Guralnik J.M.: Prognostic implications of anemia in older adults. Haematologica 2009; 94(1): 1-2.
10. Ince C.: Blood Transfusions Correct Anemia and Improve Tissue Oxygenation in Surgical and Critically ill Patients. Turk J Anesth Reanim 2017; 45(3): 119-121.
11. Xia H., Shen H., Cha W. et al.: The Prognostic Significance of Anemia in Patients With Heart Failure: A Meta-Analysis of Studies From the Last Decade. Front Cardiovasc Med 2021; 8: 632318.
12. Kung W.M., Yuan S.P., Lin M.S. et al.: Anemia and the Risk of Cognitive Impairment: An Updated Systematic Review and Meta-Analysis. Brain Sci 2021; 11(6): 777.
13. Palmer K., Vetrano D.L., Marengoni A. et al.: The Relationship Between Anaemia and Frailty: A Systematic Review and Meta-Analysis of Observational Studies. J Nutr Health Aging 2018; 22(8): 965-974.
14. Esquinas-Requena J.L., Lozoya-Moreno S., García-Nogueras I. et al.: Anemia increases mortality risk associated with frailty or disability in older adults: The FRADEA Study. Aten Primaria 2020; 52(7): 452-461.
15. Arkew M., Asmerom H., Gemechu K. et al.: Global Prevalence of Anemia Among Type 2 Diabetic Adult Patients: A Systematic Review and Meta-Analysis. Diabetes Metab Syndr Obes 2023; 16: 2243-2254.
16. Kansara A., Mubeen F., Shakil J.: SGLT2 Inhibitors in Patients with Chronic Kidney Disease and Heart Disease: A Literature Review. Methodist DeBakey Cardiovasc J 2022; 18(4): 62-72.
17. Hung K.C., Chang L.C., Ho C.N. et al.: Association Between SGLT-2 Inhibitors Use and Incidence of Anemia in Female Patients Undergoing Metabolic and Bariatric Surgery: A Retrospective Study. Obes Surg 2025; 35(10): 4402-4410.
18. Tsiftsoglou A.S.: Erythropoietin (EPO) as a Key Regulator of Erythropoiesis, Bone Remodeling and Endothelial Transdifferentiation of Multipotent Mesenchymal Stem Cells (MSCs): Implications in Regenerative Medicine. Cells 2021; 10(8): 2140.
19. Weidemann A., Johnson R.S.: Nonrenal regulation of EPO synthesis. Kidney Int 2009; 75(7): 682-688.
20. Packer M.: Mechanisms of enhanced renal and hepatic erythropoietin synthesis by sodium–glucose cotransporter 2 inhibitors. Eur Heart J 2023; 44(48): 5027-5035.
21. Kim M.K., Baek K.H., Lim D.J. et al.: Erythropoietin response to anemia and its association with autonomic neuropathy in type 2 diabetic patients without advanced renal failure. J Diabetes Complications 2010; 24(2): 90-95.
22. Sano M., Goto S.: Possible Mechanism of Hematocrit Elevation by Sodium Glucose Cotransporter 2 Inhibitors and Associated Beneficial Renal and Cardiovascular Effects. Circulation 2019; 139(17): 1985-1987.
23. Uthman L., Baartscheer A., Schumacher C.A. et al.: Direct Cardiac Actions of Sodium Glucose Cotransporter 2 Inhibitors Target Pathogenic Mechanisms Underlying Heart Failure in Diabetic Patients. Front Physiol 2018; 9: 1575.
24. Stankovic S., Miloradovic Z., Petrovic V. et al.: Redefining SGLT2 inhibitors through cytoprotective mechanisms. Eur J Pharmacol 2026; 1016: 178647.
25. Packer M.: How can sodium–glucose cotransporter 2 inhibitors stimulate erythrocytosis in patients who are iron-def icient? Implications for understanding iron homeostasis in heart failure. Eur J Heart Fail 2022; 24(12): 2287-2296.
26. Lipiński P., Starzyński R.R.: Regulacja ogólnoustrojowej homeostazy żelaza przez hepcydynę. Postepy Hig Med Dosw 2004; 58: 65-73.
27. Ghanim H., Abuaysheh S., Hejna J. et al.: Dapagliflozin Suppresses Hepcidin And Increases Erythropoiesis. J Clin Endocrinol Metab 2020; 105(4): dgaa057.
28. Matuszewski W., Tomaszek L., Szklarz M. et al.: Beyond the Cardio–Renal–Metabolic Axis: Emerging Therapeutic Targets and Novel Mechanisms of Action of Flozins. J Clin Med 2025; 14(18): 6348.
29. O’Neill J., Fasching A., Pihl L. et al.: SGLT inhibition normalizes O2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats. Am J Physiol Ren Physiol 2015; 309(3): F227-F234.
30. Safran M., Kim W.Y., O’Connell F. et al.: Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: Assessment of an oral agent that stimulates erythropoietin production. Proc Natl Acad Sci 2006; 103(1): 105-110.
31. Hare G.M.T., Zhang Y., Chin K. et al.: Impact of sodium glucose linked cotransporter-2 inhibition on renal microvascular oxygen tension in a rodent model of diabetes mellitus. Physiol Rep 2021; 9(12): e14890.
32. Wang J., Silaghi P., Guo C. et al.: Inhibition of sodium-glucose cotransporter-2 improves anaemia in mice and humans with sickle cell disease, and reduces infarct size in a murine stroke model. J Cell Mol Med 2024; 28(17): e70091.
33. Yamazaki D., Konishi Y., Morikawa T. et al.: Failure to confirm a sodium-glucose cotransporter 2 inhibitor-induced hematopoietic effect in non-diabetic rats with renal anemia. J Diabetes Investig 2020; 11: 834-843.
34. Kanbay M., Tapoi L., Ureche C. et al.: Effect of sodium-glucose cotransporter 2 inhibitors on hemoglobin and hematocrit levels in type 2 diabetes: a systematic review and meta-analysis. Int Urol Nephrol 2022; 54(4): 827-841.
35. Wang X., Fu R., Liu H. et al.: The effects of sodium glucose co-transporter (SGLT) 2 inhibitors on hematocrit levels: a systematic review and meta-analysis of randomized controlled trials. Ann Palliat Med 2021; 10(6): 6467-6481.
36. Rehman H., Postoev A., Rawat A. et al.: Dapagliflozin and Anemia Outcomes: A Systematic Review and Meta-Analysis of Effects on Hemoglobin Levels, Anemia Correction, and Incidence in Patients With and Without Heart Failure. Cureus 2025; 17(10): e95004.
37. Schwarz Y., Klein P., Lev-Shalem L.: Masked anemia and hematocrit elevation under sodium glucose transporter inhibitors: findings from a large real-world study. Acta Diabetol 2023; 61(1): 99-105.
38. Ferreira J.P., Anker S.D., Butler J. et al.: Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR-Reduced. Eur J Heart Fail 2022; 24(4): 708-715.
39. Fuchs Andersen C., Omar M., Glenthøj A. et al.: Effects of empagliflozin on erythropoiesis in heart failure: data from the Empire HF trial. Eur J Heart Fail 2023; 25(2): 226-234.
40. Sarabhai T., Kostev K.: SGLT2 inhibitor therapy and lower incidence of iron deficiency anaemia in patients with type 2 diabetes: A retrospective cohort study from Germany. Diabetes Obes Metab 2025; 27(11): 6559-6566.
41. Marques P., Matias P., Packer M. et al.: Erythropoietic response after intravenous iron in patients with heart failure and reduced ejection fraction with and without background treatment with sodium-glucose cotransporter 2 inhibitors. Eur J Heart Fail 2023; 25(12): 2191-2198.
42. Alruwaili W., Ahmad S., Berzingi S. et al.: Clinical Outcomes of Intravenous Iron Therapy in Systolic Heart Failure Patients Receiving SGLT2 Inhibitors. Am J Cardiol 2025; 254: 5-12.
43. Sánchez Fructuoso A.I., Bedia Raba A., Banegas Deras E. et al.: Sodium-glucose cotransporter-2 inhibitor therapy in kidney transplant patients with type 2 or post-transplant diabetes: an observational multicentre study. Clin Kidney J 2023; 16(6): 1022-1034.
44. Wang J., Silaghi P., Guo C. et al.: Inhibition of sodium-glucose cotransporter-2 improves anaemia in mice and humans with sickle cell disease, and reduces infarct size in a murine stroke model. J Cell Mol Med 2024; 28(17): e70091.
45. Steinmetz T., Goldman S., Kagan K.B.T. et al.: The Benef icial Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Anemia in Type 2 Diabetes-A Real-World Study. J Clin Endocrinol Metab 2025; 110(11): 3057-3065.
46. Tan G.S.Q., Morton J.I., Wood S. et al.: SGLT-2 Inhibitor Use and Cause-Specific Hospitalization Rates: An Outcome-Wide Study to Identify Novel Associations of SGLT-2 Inhibitors. Clin Pharmacol Ther 2024; 115(6): 1304-1315.
47. Packer M.: Alleviation of Anemia by SGLT2 Inhibitors in Patients with CKD: Mechanisms and Results of Long-Term Placebo-Controlled Trials. Clin J Am Soc Nephrol 2023; 19(4): 531-534.
48. Hu J.C., Shao S.C., Tsai D.H. et al.: Use of SGLT2 Inhibitors vs GLP-1 RAs and Anemia in Patients With Diabetes and CKD. JAMA Netw Open 2024; 7(3): e240946.
49. Docherty K.F., Curtain J.P., Anand I.S. et al.: Effect of dapagliflozin on anaemia in DAPA-HF. Eur J Heart Fail 2021; 23(4): 617-628.
50. Ferreira J.P., Anker S.D., Butler J. et al.: Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR-Reduced. Eur J Heart Fail 2022; 24(4): 708-715.
51. Oshima M., Neuen B.L., Jardine M.J. et al.: Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial. Lancet Diabetes Endocrinol 2020; 8(11): 903914.
52. Koshino A., Schechter M., Chertow G.M. et al.: Dapagliflozin and Anemia in Patients with Chronic Kidney Disease. NEJM Evid 2023; 2(6): EVIDoa2300049.
53. Madero M., Chertow G.M., Mark P.B.: SGLT2 Inhibitor Use in Chronic Kidney Disease: Supporting Cardiovascular, Kidney, and Metabolic Health. Kidney Med 2024; 6(8): 100851.
54. Del Vecchio L., Peiti S., Pucci Bella G. et al.: SGLT2 Inhibitors in Glomerulonephritis: Beyond Nephroprotection? J Clin Med 2025; 14(10): 3533.
55. Schwarz Y., Klein P., Lev-Shalem L.: Masked anemia and hematocrit elevation under sodium glucose transporter inhibitors: findings from a large real-world study. Acta Diabetol 2023; 61(1): 99-105.
56. Doi Y., Hamano T., Yamaguchi O. et al. Canagliflozin may increase thromboembolic events in males with erythrocytosis but not in females. Blood Adv 2025; 9(13): 3202-3212.
57. Koshino A., Heerspink H.J.L., Jongs N. et al.: Canagliflozin and iron metabolism in the CREDENCE trial. Nephrol Dial Transplant 2025; 40(4): 696-706.
58. Wanner C., Lachin J.M., Inzucchi S.E. et al.: Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease. Circulation 2018; 137(2): 119-129.
59. „Rejestr produktów leczniczych”; https://rejestry.ezdrowie. gov.pl/rpl/search/public (dostęp 8.12.2025).
60. Liu J., Chin-Yee B., Ho J. et al.: Diagnosis, management, and outcomes of drug-induced erythrocytosis: a systematic review. Blood Adv 2025; 9(9): 2108-2118.
61. Tukker M., Bruwiere E., Bos S. et al.: SGLT2 Inhibitor-Related Polycythemia in a Patient With Chronic Heart Failure: A Potential Severe Adverse Event. Circ Heart Fail 2023; 16(7): e010613.
62. Chin-Yee B., Solh Z., Hsia C. et al.: Erythrocytosis induced by sodium-glucose cotransporter-2 inhibitors. Can Med Assoc J 2020; 192(42): e1271.
63. Lewis M., Burrack N., Heymann A. et al.: Sodium-Glucose Cotransporter 2 Inhibitors, Erythrocytosis, and Thrombosis in Adults With Type 2 Diabetes. JAMA Netw Open 2025; 8(6): e2517086.
64. Motta G., Zavattaro M., Romeo F. et al.: Risk of Erythrocytosis During Concomitant Testosterone and SGLT2-Inhibitor Treatment: A Warning From Two Clinical Cases. J Clin Endocrinol Metab 2019; 104(3): 819-822.
65. Gosmanov A.R., Gemoets D.E., Schumacher K.A.: Increased risk of erythrocytosis in men with type 2 diabetes treated with combined sodium-glucose cotransporter-2 inhibitor and testosterone replacement therapy. J Endocrinol Invest 2024; 47(10): 2615-2621.
Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne – Na tych samych warunkach 4.0 Międzynarodowe.
Prawa autorskie (c) 2026 Review of Medical Practice